Small molecule · Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα, p (PIK3CA) · developed by Relay Therapeutics
Zovegalisib is an orally bioavailable, mutant-selective inhibitor of the PI3Kα catalytic subunit encoded by PIK3CA. It allosterically binds mutant forms of PIK3CA, blocking signaling through the PI3K/Akt/mTOR pathway. It is being studied in PIK3CA-related overgrowth and vascular malformation syndromes and in HER2-negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06982521 | Phase 3 | PIK3CA Mutation | Recruiting | RLAY |
| NCT06789913 | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS) | Recruiting | RLAY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Breast CancerBreast CancerCLOVES SyndromeHER2- Negative Breast CancerHormone Receptor Positive TumorKlippel Trenaunay SyndromeLymphatic MalformationsMetastatic Breast CancerPIK3CA MutationPIK3CA-Related Overgrowth Spectrum (PROS)Vascular AnomaliesVascular Malformations
Updated Nov 1, 2026. Something wrong or missing? Report it on the RLAY page.
See RLAY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RLAY catalysts and pipeline →